Cargando…
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab
Patient: Male, 58-year-old Final Diagnosis: Atypical hemolytic uremic syndrome • FEIBA induced aHUS Symptoms: Anemia • renal failure • thrombocytopenia Medication: — Clinical Procedure: — Specialty: Hematology • General and Internal Medicine OBJECTIVE: Challenging differential diagnosis BACKGROUND:...
Autores principales: | Tsai, Hsin Hsiang Clarence, Moyers, Justin Tyler, Moore, Christie J., Thinn, MieMie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959102/ https://www.ncbi.nlm.nih.gov/pubmed/33678802 http://dx.doi.org/10.12659/AJCR.929616 |
Ejemplares similares
-
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018) -
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017) -
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021) -
The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022)